In 1978 the soft tissue sarcoma group merged with the international osteo-sarcoma working party to form the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). The emphasis in the studies has always remained the treatment in first and second line of advanced soft tissue sarcoma patients. It has led to a priceless collection of data in Brussels of over 3.000 patients stored under the careful guidance of R. Sylvester and since 1989 of M. Van Glabbeke, the Group's statisticians. Next to the study of many new agents, the Group has developed very strict quality control procedures and played a major role in the development of the RECIST criteria. In the recent past studies in Ewing sarcoma and several subtypes of soft tissue sarcomas have been initiated. It should be mentioned that the international recognition of this Group has led to a track record of at least one oral presentation at every ASCO and ECCO-ESMO meeting since 1984. Of course major publications, not only in books, but also in the Journal of Clinical Oncology, the European Journal of Cancer, the Annals of Oncology, the British Journal of Cancer and the Journal of the National Cancer Institute but also in the New England Journal of Medicine and the Lancet have appeared. The future looks bright: in view of the fact that the Group plays a pivotal role not only in the clinical development of the new molecular targeted therapies but also performs translational research in its present studies. The number of participating institutions and countries will certainly increase in the next decades.
Future clinical trial design of soft tissue sarcoma studies J. VERWEIJ (Rotterdam Cancer Institute and University Hospital, 3075 EA Rotterdam, The Netherlands)
Until recently most soft tissue sarcomas, due to the relatively low incidence of these diseases, have been treated and studied grouped together as if they were one disease. Retrospective analyses of large databases have however identified certain subtypes that tend to respond differently from others and the increased knowledge should guide us to a better differentiated trial design. In addition, due to the increased knowledge of molecular biology and the improved molecular diagnostics more and more specific receptors on the cell surface have been identified that can be used as targets for anticancer treatment. Frequently these receptors are specifically overexpressed in specific subtypes of sarcomas and this increasing knowledge should also lead to a more targeted treatment. Inhibitors of these more selective targets are currently in development. Examples are inhibitors of signal transduction, inhibitors of farnesyltransferase and inhibitors of angiogenesis or matrix metallo proteinase. Importantly, many of these latter agents, in in vitro and in vivo models, mainly exhibit growth inhibition rather than tumour regression. This aspect is also important to take into account when designing a trial. If tumour regression can not be expected, phase II studies seem rather useless. Once time to progression and/or survival become the main endpoint, the phase IIB or preferably phase III trial design becomes the preferred one. Obviously, moving from phase I directly to phase II would involve a giant leap of faith. Intermittent alternative trial designs are therefore currently under consideration. Whatever the issue, it is clear that in the near future we will more and more witness the design of large trials as well as the design of trials in specific subtypes of sarcomas or even a more general approach of targeting a molecular target regardless of subtype. Examples of these are the potential use of conventional cytotoxics such as Taxol for angiosarcomas or Ifosfamide in synovial sarcomas, but also the more recently developed agents, such as STI 571 in C-kit overexpressing sarcomas or agents directly towards the ppar-ligand in liposarcomas. The specificities of these trial designs will be discussed in detail.
How should we measure treatment effects: progression free survival as the primary end-point? M. VAN GLABBEKE (EORTC Data Center, Brussels, Belgium) Introduction: The aim of this presentation is to explore whether and when we can recommend progression free survival as the principal end-point for phase II trials on soft tissue sarcoma. For which agents? Response to therapy, based on measured decrease in the size of cancer lesions, is the most effective endpoint to document biologic anticancer activity of cytoreductive agents and consequently to identify potential new cytoreductive drugs. The RECIST criteria provide an harmonized method of response evaluation. For non cytoreductive anticancer agents, biologic activity is not expected to translate into shrinkage of lesions, but rather in stabilization of progressive disease. The RECIST guidelines recognize that progression free survival and/or time to progression may be a valuable alternative end-point to provide an initial estimate of biologic effect for those agents. Statistical designs: The classical phase II designs (Simon, Fleming, Gehan) are only applicable to phase II trials with a binary primary end-point (success vs failure). Success can be defined as absence of objective progression (as defined by the RECIST criteria) at a fixed selected time point (i.e. 3 or 6 months), if all patients are followed until this point. This is a valid end-point only if disease progression has been documented before starting therapy. Target success rates: Two baseline parameters are needed to compute the sample size and decision rules with those designs: the minimum success rates (i.e. progression free -PF-rate) expected from an active drug (P1) and the maximum success rate expected if the drug is inactive (P0). The success rate observed with the best available regimen for the targeted patient population is generally used as P1. We have estimated relevant PF rates for soft tissue sarcoma trials from the STBSG database. For non pre-treated patients, PF rates for active regimen were estimated from the data of 1154 patients treated with 1st line anthracycline containing chemotherapy, with an externally reviewed diagnosis of leiomyosarcoma (531), mfh (217), synovial sarcoma (115), liposarcoma (110), fibrosarcoma (68) and neurogenic sarcoma (113). The 3 months estimated PF rates varied from 77% (synovial sarcoma) to 58% (leiomyosarcoma) and the 6 months PF rates from 56% (synovial sarcoma) to 38% (mfh). In 61 leiomyosarcoma from GI origin (now identified as GIST), those figures were 44% and 30% respectively. For pre-treated patients, PF rates for active regimen were estimated from 124 patients treated with ifosfamide or DTIC, after failure of anthracycline containing regimen. Overall PF rates at 3 and 6 months were estimated to be 44% and 18% respectively. PF rates for inactive regimen were estimated from 253 patients included in 2nd line trials with 9 agents that did not demonstrate activity. In those patients, the overall PF rate at first disease evaluation (6 to 8 weeks after treatment start) was 21%. Conclusion: Progression free rates may be appropriate primary end-points for phase Ii trials with non cytoreductive agents in soft tissue sarcoma, but the patients' selection, follow-up period and parameters of the statistical design need to be adapted.
Evaluation and presentation of clinical trial data on sarcomas I. JUDSON (Royal Marsden Hospital, London, UK)
The problem: Soft tissue sarcomas (STS) are a heterogeneous group of disparate diseases. Outcome is determined by disease site, tumour size, grade and histological subtype. Nevertheless, owing to their rarity, and the paucity of effective treatments, it remains common practice to conduct Phase II and Phase III trials of chemotherapy regimens in mixed populations of patients. Trials of adjuvant chemotherapy provide an example of the difficulty caused by this process. Individually these have generally failed to demonstrate a survival benefit. 1 In part this is due to their small size, in part patient heterogeneity. The meta-analysis reported in 1997 2 aroused controversy owing to the inclusion of studies involving patients with particularly poor prognosis, e.g. uterine sarcoma, and patients with indolent, low grade tumours, and also the use of low dose regimens that would not conform to current ideas of best practice. Overall the results showed a benefit from treatment in terms of disease-free but not overall survival. Nevertheless, the debate served to highlight the results of the Italian Sarcoma Group study reported by Frustaci et al 3 which shows a survival advantage for aggressive chemotherapy in selected patients with extremity and limb girdle high grade tumours. Maturing data from this small trial appear to confirm the early results.
How then are we to judge the results of studies carried out in mixed populations of patients? Assessing clinical trial data: Firstly, it is necessary to look carefully at all the known prognostic factors. Retrospective studies have been conducted using the EORTC Soft Tissue and Bone Sarcoma Group database of over 2,000 patients treated for advanced or metastatic disease with anthracycline-containing chemotherapy. These act as an excellent source of unbiased information. It has been demonstrated that favourable factors for a response to chemotherapy are: absence of liver metastases, young age, high grade and liposarcoma. Similarly, longer survival is associated with: low grade, good performance status, long disease-free interval from diagnosis, young age and absence of liver metastases. 4 In a separate study it was shown that patients with small metastases only in the lung are most likely to respond to chemotherapy. 5 With regard to histological type, apart from the favourable response in the case of liposarcoma, the converse is clearly true for visceral tumours, especially gastrointestinal stromal tumours (GISTs) which rarely, if ever respond to cytotoxic chemotherapy. In other words, if a Phase II study in advanced STS reports a 60% response rate using a standard chemotherapy combination, it most probably means that the investigators have selected young, fit patients with extremity, high grade tumours, who have lung-only, low volume metastatic disease. If the authors are unwise or unscrupulous they may wish to persuade us that their excellent results are due to their special 'recipe', especially if dose escalation has been used. This sort of bias can only be excluded by performing randomised trials. For example an EORTC Phase II study used GM-CSF to allow escalation of the dose of doxorubicin from 50 to 75 mg/m 2 in combination with ifosfamide. An excellent response rate of 45% was obtained. 6 Unfortunately, in a subsequent randomised trial there was no advantage for the higher dose of doxorubicin. 7 Similarly, in a randomised Phase II trial comparing standard doxorubicin versus liposomal doxorubicin (DOXIL®/ CAELYX®) both arms performed poorly with response rates of only 9% and 10%. 8 The latter response rate in a single arm study would have resulted in the conclusion that CAELYX® was inactive. Increasingly, our improving understanding of sarcoma biology is resulting in the ability to treat individual tumour types selectively. The demonstration that agonists of the peroxisome proliferator-associated receptor gamma (PPAR ) such as troglitazone, cause differentiation of certain types of liposarcoma offers hope of improved therapy in this disease type. 9 Recently, the introduction of a receptor tyrosine kinase inhibitor for the treatment of GISTs seems set to transform our ability to treat this otherwise refractory disease. The introduction of such new treatments will set the standard for defining the patient population under study, since response will be determined by expression of the appropriate receptor.
Presentation of trial data: In conclusion, in order for your data to be meaningful to others, it is vital to include all the data you would like to see for yourself. All prognostic information needs to be included. Any known bias in patient selection should be transparent, and excessively optimistic claims should be avoided. Wherever appropriate, molecular diagnostic techniques should be used to clarify exactly what population of patients has been treated. The precise methods used to assess treatment benefit need to given in detail. In most cases promising results will require confirmation in Phase III trials. JF, et al. Br J Cancer 1995; 72:469-475 2 Sarcoma Meta-analysis Collaboration. Lancet 1997; 350:1647 -1654 3 Frustaci F, et al. Proc Am Soc Clin Oncol 1999 18:546a (abstr. 2108) 4 Van Glabbeke M, et al. J Clin Oncol 1999; 17:150-157 5 Van Glabbeke M, et al. Proc Am Soc Clin Oncol 1999; 18:542a (abstr. 2093 ) 6 Steward WP, et al. Cancer Chemother Pharmacol 1993 31 suppl 2 S241-244 7 Le Cesne A, et al. J Clin Oncol 2000; 18:2676 -2784 8 Judson I, et al. Eur J Cancer 2001 , in press. 9 Demetri G, et al. Proc Am Soc Clin Oncol 1999 18:535a (abstr. 2064) With the publication of the human genome sequences and the identification of around 40,000 human genes a major challenge that now faces the scientific currently is how to use this information to help cancer patients. One very powerful platform that can be used to achieve this goal is microarray technology that allows many thousands of genes to be examined simultaneously. We have through the setting up of ICR 'spotted microarray facility' used this technology in a number of distinct strategies. CB30865 is a drug of unknown mechanism of action that has activity against a broad range of tumour cell lines. To investigate the molecular basis of resistance to CB30865 we have used microarray technology to compare gene expression in a tymphoblatoid cell line W1L2 with a variant of this line W1L2:R865 that shows a 300-fold increase in resistance CB30865. cDNA probes prepared from the W1L2 cell line and from the W1L2:R865 cell line were hybridized simultaneously to a microarray of 7,000 clones randomly selected from a cDNA library prepared from the W1L2:R865 cell line. These studies led to the identification of MSS1 which encodes a component of the 26S Proteosome complex as a gene whose level of RNA expression correlated with drug resistance. Based on these observations a derivative of CB30865 called CB300919 was tested and subsequently discovered to be an inhibited of cellular proteosome activity. We have also used microarray technology to identify genes that are amplified and overexpressed in human cancer. As a test system initially to determine that the procedure was working used the breast cancer cell line BT474 which contains amplicons at 17q11-21 17q22-23 and 20q13. A microarray of 10,000 clones randomly picked a cDNA library prepared from the BT474 cell line was hybridised n comparative genomic hybridisation (CGH) experiments to DNA from BT474 cells and to control muscle DNA. These studies identified 68 amplified genes from the three chromosome 17 and chromosome 20 amplicons and studies on gene expression were used to identify from these 5 new candidate oncogenes. This procedure has now been applied to several amplicons in human sarcomas and the results will be presented.
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Controversy still exists over the correct classification of some groups of sarcomas. Particularly it has been proposed that malignant fibrous histiocytoma may in most cases be reclassified pleomorphic leiomyosarcomas, rhabdomyosarcomas or liposarcomas. We are currently using microarray technology to collect expression profiles of primary sarcomas and using hierarchical clustering to determine the relation of MFH tumour to other tumour groups. Preliminary results of these analyses will be presented. The title chosen for this talk by the organisers is, of course, provocative and deliberately naïve. There is no question that cytogenetics and molecular genetics have had significant impact on our understanding of mesenchymal neoplasia and, in certain circumstances, on our ability to make objective and more reproducible diagnoses. There is also some limited evidence to suggest that molecular genetic data may provide prognostic information in certain tumour types. The role of gene expression profiling is, as yet, largely unexplored but to date has only validated conventional pathologic subclassification in other types of cancer. However, the notion that these techniques will supplant conventional histopathological analysis within the coming 20-25 years is essentially laughable for the following four major reasons:
1. In simple numerical terms, the majority of soft tissue sarcomas do not show any specific, consistent or currently detectable cytogenetic or molecular genetic abnormality; 2. In light of their morphologic heterogeneity, a substantial proportion of soft tissue sarcomas can only be recognised as such by conventional histopathology-there are no surrogate molecular genetic markers of malignancy; 3. The technologies required to take optimal advantage of molecular genetic/cytogenetic analysis are available in very few centres and are often poorly integrated with clinical need; 4. Cost constraints, the need for appropriately trained staff and the relative rarity of soft tissue sarcomas combine to make it very improbable that most institutions will establish and utilize molecular genetic techniques in the foreseeable future.
The fact remains that conventional pathologic analysis, in particular accurate histologic subtyping and (in some circumstances) grading, provides the most crucial information in terms of diagnosis, prognosis and determination of therapy in soft tissue sarcoma patients. Furthermore, the wide availability of this diagnostic methodology, its exceptional cost effectiveness and the relative ease with which tissue samples (or slides) can be shared with other pathologists (or treatment centres) make it highly unlikely that this approach will be superceded in our lifetimes. Having said that, molecular genetic approaches will unquestionably bring new information and insights which in, in combination with the constant advances in clinicopathologic assessment of these tumours, will help to refine diagnosis, classification and prognosis, at least in some major academic centres. The two main goals in the coming decades should be a) to facilitate a collaborative/ integrated approach between clinical and more basic scientists working on soft tissue sarcomas in pathology/oncology and b) to ensure that as many patients as possible are treated in specialist centres, in which best advantage can be taken of any diagnostic and prognostic advances.
The impact of molecular genetics on the future management of sarcomas L. HELMAN (National Cancer Institute, Bethesda, Maryland, USA) The increasing application of molecular techniques in sarcomas is having significant impact on our ability to diagnose, make prognostic predictions and treat a variety of sarcomas. The discovery of recurrent reciprocal translocations in a variety of sarcomas and the subsequent cloning of the resultant fusion genes have fueled a major change in the diagnostic criteria for such tumors. The ease and widespread application of RT-PCR enables pathologists to confirm or question diagnoses based on molecular criteria. Furthermore, translocation-derived fusion proteins have recently become the target of immunotherapy approaches. Specific technological advances are also beginning to profoundly affect the management of sarcomas. The increasing ease of sequencing tumor DNA has led to the identification of specific point mutations in genes leading to alter signaling of the tumor cells. This finding, in turn, has led to a widespread effort to develop drugs specifically targeting the! se altered signaling pathways. A recent example of the success of this approach is the use of STI 571 in treating GIST tumors, where the drug specifically targets the alteration in the c-Kit gene seen in these tumors. More recently, the application of expression profiling or array technology to sarcomas has the potential to further refine the classification of these tumors and identify new potential therapeutic targets. We are just beginning to see the potential power of high-throughput SNP technology to identify risk categories and critical signaling pathways in these tumors. Illustrations of these approaches and their effects on clinical management of specific tumors will be discussed.
Medical imaging of soft tissue sarcomas
We will present the ability of magnetic resonance imaging in staging, grading, tissue characterization, percutaneous biopsy, and post therapeutic surveillance of soft tissue tumours. Well known staging parameters such as extent, relationship with adjacent structures, and detection of intralesional necrosis are used in the MR protocol for locoregional staging. Bone scintigraphy and high resolution CT scan of the lungs are best methods for ruling out metastatic spread. A variety of (solitary or combinations of) grading parameters is described in radiological literature. The role of MR imaging is to afford recognition of these lesions that need further aggressive work-up, excluding all others. Despite controversial reports, the definite role of MR imaging in grading of soft tissue tumours seems to become established. As for grading, a lot of individual parameters used for tissue characterization have low sensitivity, but combinations of these parameters (age, site, signal intensities, …) are more useful and often allow to predict a specific diagnosis or to narrow down the list of differential diagnosis. Local recurrences of soft tissue tumours are frequent and can be detected accurately by an 'easy-to-use' MR algorithm. A comparative study between MRI and 'whole specimen' histopathology proves that the MR signal of different tumour components can easily be explained by their different histological composition but that the creation of MR prototypes of various soft tissue tumours is illusory because of tumour components may be intermingled, change in time and sometimes have adverse effects on the overall MR signal intensity. Moreover cellularity, extent of extracellular spaces and relationship between nuclear and cytoplasmatic size will influence signal intensity on different pulse sequences. The value and risks of percutaneous biopsy will shortly be highlighted. Over the last years, positron emission tomography (PET) has gained widespread enthusiasm as an innovative technique in oncology. In contrast to conventional imaging techniques, such as computed tomography (CT), ultrasound (US), and magnetic resonance imaging (MRI), which are based on differences in density of tissues, PET relies on the differences in metabolism of cancer cells. For instance, most tumour cells have a higher rate of glycolysis in comparison with non-neoplastic cells. This change in carbohydrate metabolism can be visualized with PET using the radioactive glucose analogue called fluorodeoxyglucose (FDG) . PET has the possibility of imaging the whole body within one image session (frequently used in staging procedures) and is able the quantify changes in metabolism, a parameter of use in evaluating the aggressiveness of the tumour or assessing response to treatment. Although the experience of PET in oncology is growing fast, data on the value of PET in the management of sarcomas is limited and mainly focusing on the ability of FDG-PET in differentiating benign from malignant (mostly soft tissue) masses. FDG uptake in high-grade sarcoma proved to be significantly higher than those of benign or low-grade tumours, although there was a substantial overlap between the groups. Also the pattern of FDG within the mass seemed related to the histopathologic grade: very heterogeneous in high-grade and uniform or absent in the low-grade ones. Further insight in the association between FDG uptake and other pathologic features was given by Folpe et al. 1 who found that FDG uptake was associated not only with histopathological grade but also with cellularity, mitotic activity, MIB labeling index, and p53 overexpression. Since clinical management is depending on histopathologic grading and sarcomas are heterogeneous neoplasms, FDG-PET may help ensure accurate grading by guiding biopsy toward the most biologically significant regions of large masses. Further follow-up will be necessary to determine whether FDG-PET provides independent prognostic information. Data on the value of FDG-PET in detection of disease extend is limited. Lucas et al. 2 evaluated the capacity to identify local recurrence (compared to MRI) and pulmonary metastases (compared to CT) in 62 patients with soft-tissue tumours after treatment. For the detection of local disease, MRI proved to be more accurate than PET whereas for the identification of lung metastases, CT proved to be the most sensitive and PET the most specific technique. The major advantage of PET was its ability to detect other metastases at unexpected sites. Finally, PET can be used to evaluate the effect of treatment.
Since metabolic changes precede the morphological ones, PET seems a promising tool to discriminate responders from nonresponders, more accurate and much earlier than anatomical imaging. Schulte et al. 3 evaluated the use of PET in estimating the grade of tumour regression after neoadjuvant chemotherapy in 27 patients with osteosarcoma prior to surgery. The decrease of FDG uptake showed a close correlation to the amount of tumour necrosis induced by chemotherapy. With a cut-off level of 0.6, all responders and 8 of 10 non-responders could be identified. In an ongoing study in our own hospital in patients with GIST tumours treated with the experimental drug STI 571, a very rapid decline in FDG uptake (as soon as 48hours after the initiation of therapy) was observed in 12/22 patients, often corresponding with symptom relief. In the 6 patients with an early increase in FDG uptake, a rapid deterioration of clinical symptoms was seen. While there was a clear discrimination between responders and non-responders on PET, no major change in tumour volume was observed on CT.
With the introduction of new, often non-cytotoxic drugs, no major changes in tumour volume is to be expected and therefor therapy evaluation based on metabolic changes will be become more and more important. These are just some of the questions which surgeons ask themselves and their colleagues from time to time. These questions have been circulated in advance of the meeting to an interested group of STS surgeons-their responses have been analyzed and will be discussed in an attempt to define what questions really do need answering and how we might go about this.
Which questions in radiotherapy need to be answered in future studies? B. O'SULLIVAN (Princess Margaret Hospital, Toronto, Canada) Introduction: The use of adjuvant radiotherapy (RT) has greatly expanded the opportunities for conservative surgery in soft tissue sarcoma (STS). Although ample evidence of efficacy exists, the best way to use RT (or sometimes its indications) remains unclear. This presentation will focus on STS and will address a number of continued controversies while recognizing that current strategies provide high rates of local control in many sites. Omission of RT: Undoubtedly a favorable population exists where RT is unnecessary with appropriate surgery (e.g. well contained lesions) but the limits of this approach are uncertain. In contrast, there are unfavourable groups where radiotherapy may also not be useful, and the prognosis is universally poor, e.g. retroperitoneal sarcoma (RPS). Certainly in RPS a randomized trial addressing this issue would be valuable since patients are often destined to die with present approaches, which are both potentially toxic as well as inadequate. In the more favorable lesions criteria for selection are needed and should be applied and studied prospectively to determine selection for surgery alone. Reducing Toxicity of RT: The prospective trials have yielded information but questions remain. In the Canadian SR2 trial, total dose and increased volume was associated with long term limb fibrosis. Strategies to reduce the total dose of radiotherapy delivered, or the biologic dose through exploitation of optimal fractionation approaches have not been addressed prospectively. In the future, it may also be possible to prospectively evaluate radioprotective agents, or replacement of damaged tissue at the macroscopic or cellular level. Opportunities to protect tissues by exclusion from the target volume should be exploited and studied. This is especially important where tissues are critical and dose limiting. The potential to treat RPS with untethered bowel displaced by an unresected tumor offers potential gain with preoperative RT. In this scenario, there is minimal contamination of the abdominal cavity, the tumor vascularity is intact, and the fields are smaller. This approach could readily be the focus of a trial supported by those who are discouraged by the value of post-operative RT in RPS where RT administration is difficult to administer. Assessment of Toxicity: The SR2 trial also revealed that volume irradiated is strongly associated with poor function and limb edema. Yet we are unaware whether this relates to total proportional volume of the limb treated or to proportion of the cross-section of the limb irradiated. In order to address such issues prospective valid and reliable measures of toxicity must continue to be developed and accurate documentation of treatment implemented. Definition of Target Volumes: Because volume is important there is an urgent need to define the volume at risk. Clinico-pathologic studies are needed for radiotherapy planning to permit reduction in normal tissues irradiated. The significance of peritumoral edema on MRI is unknown. This and other imaging knowledge (e.g. PET) must be evaluated to permit optimum surgical and radiotherapy target delineation. Optimum Volume and Combined Modality Approaches: Knowledge of optimum volume will provide the opportunity to combine concurrent chemotherapy with radiotherapy and spare morbidity by treating smaller volumes with conformal plans, high-resolution intensity modulated radiotherapy (IMRT), or brachytherapy. The comparative benefits of these and other approaches (e.g. limb perfusion) requires study from the context of cost, wound healing, function, combined chemoradiotherapy toxicity and, of course, local control. Summary: The evaluations described provide much opportunity for future research in the use of RT in STS and will be discussed with examples. Background and introduction: Some sixty percent of Soft Tissue Sarcomas (STS) occur in the limbs Amputation used to be the standard treatment for these extremity lesions but it has now been replaced by limb-sparing surgery in about 90% of patients, without significant impairment of limb function. In the remaining 10% the tumour involves the neurovascular bundle, is very large, is close to an articulation or consists of multiple nodules. In these settings, treatment remains primary amputation and radiotherapy is ineffective. Sadly, however, amputation does not improve life expectancy, because distant micrometastases, mainly pulmonary have usually already grown. We reported that Isolated Limb Perfusion with TNF/IFN gamma and melphalan (TIM-ILP) is an efficient treatment of inoperable soft tissue sarcomas and melanoma of the extremities (1). Moreover, this treatment is a limb-sparing neoadjuvant therapy when it is followed by removal of the tumour remnant(s) (2). Method: The rationale is that isolated perfusion allows high regional concentration of drugs, respectively TNF which targets tumour associated vessels, and melphalan, an alkylating agent, which targets tumour cells (3). The technique is sophisticated and requires a multidisciplinary team of surgeons with know how in extremity surgical oncology and isolated limb perfusion procedure, anaesthesiologists specialised in intensive care, nuclear medicine specialist for continuous monitoring of leakage to the general circulation, and pump technicians familiarised with hyperthermic isolated limb perfusion. The procedure includes the surgical isolation of the limb major vessels and their connection to the extracorporeal circuit, under tourniquet. For TM-ILP, high dose TNF (3 mg upper or 4 mg lower limb) is administered when no substantial leakage is detected and when tissue temperature reaches 38ºC. In the past, for TIM-ILP 0.2 mg IFN gamma was added. High dose melphalan is administered 30 min later, when vascular permeability has been increased by TNF. Perfusion ends after 90 min and the limb vessels are intensively washed of residual drugs. The whole procedure takes around 5 hours. For safety reason, the patient is admitted in intensive care unit for at least half a day. Results: The European TNF/ILP Assessment Group evaluated 260 patients with irresectable STS enrolled in 10 years into four studies with similar protocols to determine whether TM (TNF/ melaphalan) or TIM (TNF/IFN gamma/melaphalan)-ILP offers durable limb salvage by effective local control of the tumour with or without subsequent surgery (4, 5). Patients were reviewed by an Independent Review Committee and compared with conventionally treated patients (often by amputation) of a population-based Scandinavian STS Database, since randomised studies were never considered in view of the high response rate and high limb sparing obtained after TM or TIM-ILP. The proportion of patients who had achieved durable limb salvage ranged from 74% to 87% in the four studies and the objective (complete plus partial) response rates were 56.5-82.6%. The Independent Review Committee considered that 80% of all enrolled patients met the criteria for irresectability. As proven by matched-pair comparison, the ILP treated patients survived as long as conventionally treated patients from the Scandinavian STS Database. In Lausanne, we reviewed our results as a single centre performing TIM or TM-ILP as a limb salvage treatment for initially nonresectable soft tissue sarcomas of the extremities (6). Twenty-two patients (6 men and 16 women; 3 upper limb and 19 lower limb tumours) were enrolled. AJCC stage was IIA in 4 patients, III in 7 and IV in 11. Thirteen cases were recurrences or progressions after previous therapy; 5 tumours had a diameter 20 cm, and 4 were multiple or regionally metastatic. There were 6 malignant fibrous histiocytomas, 5 liposarcomas, 4 malignant schwannomas (malignant peripheral nerve sheet tumours), 3 rhabdomyosarcomas, 2 leiomyosarcomas, 1 recurrent extrasquelettal osteosarcoma and 1 angiosarcoma. Twenty-four ILPs were performed in the 22 patients; 18 (82%) experienced an objective response: it was complete in 4 (18%) and partial in 14 (64%). Three patients had minimal or no response and the tumour progressed in one case. All patients had fever for 24 hours but only one developed a grade 3 reversible distributive shock syndrome with no sequellae. There was no grade 4 toxicity. Seventeen patients (77%) underwent limb sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and 7 extracompartmental. Surgery included flaps or skin grafts in 5 patients, arterial replacement in 2 and knee arthrodesis in 1. Adjuvant chemotherapy was given to 8 patients and radiotherapy to 6. One patient had to be amputated after second ILP. Secondary amputations were performed for recurrence in two patients, resulting in an overall limb salvage of 19/22 (86%). After a median follow up of 28 months, 10 recurrences were recorded: 7 were both local and systemic and 3 were only local. The median disease free and overall survival have been > 12.5 and 18.7 months respectively: this is similar to the outcome after primary amputation for similar cases. Conclusion: We conclude that ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori nonresectable limb soft tissue sarcomas, a condition that only represents 10% of limb STS. The procedure is sophisticated and costly, it requires continuous experience of a multidisciplinary team. For performing at least one ILP per month, only one centre is needed for a 5 million population basin. We recommend the implementation of an European Quality Assurance Programme.
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1 Lienard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ 1992, High-dose recombinant tumour necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma: Journal of Clinical Oncology, v. 10, p. Purpose: To evaluate the efficacy of neoadjuvant chemotherapy combined with regional hyperthermia (RHT) in adult patients with non-metastatic high-risk soft tissue sarcomas (HR-STS). We report upon the results of two consecutive phase II studies and present a subgroup analysis for patients with retroperitoneal and visceral HR-STS.
Patients: 113 patients with HR-STS (non-resectable primary/S1, recurrent/S2, inadequately resected/S3) located within extremities, trunk or abdomen were treated within a neoadjuvant phase II protocol (RHT-91 or RHT-95). HR-criteria were: tumor grade II/ III + tumor size (>8cm for RHT-91; >5cm for RHT-95) + extracompartmental extension. The RHT-91 protocol (59 pts) included 4 cycles of preoperative chemotherapy (XT) plus RHT, followed by surgery and 4 cycles of adjuvant XT plus RHT. In addition, R1/R2-resected pts received radiation. The RHT-95 protocol (54 pts) was identical except that pts after surgery obtained XT without RHT and adequate radiation regardless of resection status. XT of both studies consisted of etoposide (125mg/m 2 ) on day 1+4, ifosfamide (1500mg/m 2 ) on day 1 to 4, and adriamycin (50mg/m 2 ) on day 1 (EIA). RHT (1hr at 42.5ºC) was given on day 1+4.
Results: Radiographic response in 52 evaluable pts of the RHT-91 (42%) and in 32 assessable pts of the RHT-95 study (28%) included 1+0 CR, 8+5 PR, 13+4 MR, 17+10 SD and 13+13 PD, respectively. Among 74 pts undergoing surgery, amputation rate was <15%. After different median observation times (RHT-91: 58mo/ RHT-95: 30mo) probability of overall survival (42% vs 48%; p = 0.392) and distant progression free survival (51% vs 64%; p = 0.357) are quite similar for both studies. Subgroup analysis (S3 vs S1, S2) for overall survival revealed also no significant difference (47% vs 48%; p = 0.616). Interestingly, local relapse free survival was in favour of the RHT-91 study, which included pre-and postoperative RHT (58% vs 57%; p = 0.021). Among these patients, we performed also a subgroup analysis for 58 HR-STS with retroperitoneal or visceral (RP/V) STS. Radiographic response after neoadjuvant thermochemotherapy was assessable in 40 patients (5 PR, 8 MR) with no overall response rate of 33%. After completion of protocol treatment, 25 patients (43%) had no evidence of disease (NED). 5-year probabilities of only local failure-free, any local failure-free, distant metastasisfree, event-free and overall survival (OS) were 53%, 25%, 51%, 20% and 32%, respectively. Median OS was 31 months for the entire study cohort, while OS was in favor of patients with NED vs. NON-NED status (76 vs. 20 months; P = .0001). Patients responding to neoadjuvant thermochemotherapy associated significantly with NED (P = .008). At 5-year follow-up, probability of OS was in favor of patients responding to neoadjuvant thermochemotherapy (60% vs. 10%; P = .0014).
Conclusions: Based on these results, a randomized prospective phase III intergroup study (EORTC 62961/ESHO RHT-95) with transatlantic participation is ongoing comparing EIA +/-RHT in previously defined (S1-S3) risk groups and includes pre-and postoperative RHT in the experimental treatment arm. Since July 1997 more than 100 pts have been randomized and treatment within this protocol is feasible and safe while impact on local disease control and survival has to be awaited. The major advantage is however obtained in delaying the relapse either locally or at the lung level, whereas the amount of distant events is similar in both arms (JCO, vol. 19 (5);2001). -subgroups analysis: Beside the intention to treat analysis, further aspects have been looked at: Efficacy of chemotherapy (efficacy), exclusion from the analysis of those patients never starting chemotherapy (7 patients in the treatment group); Impact of the dose intensity (D.I.), comparison of those pts receiving a D.I. 85% versus <85% and versus the control group; Evaluation of the postrelapse survival (Post-rel-Surv), comparison of the survival of treated and untreated groups after the relapse. Preliminary data: the analysis of the three above mentioned aspects also seem to indicate the usefulness of adequate chemotherapy in the adjuvant setting in a high risk patient population.
Conclusions:
The present Italian trial, with an adequate follow-up, strongly indicates the activity of adjuvant chemotherapy in a highrisk patient population. This efficacy and gain in survival is however mainly due to a delay in relapse either local or at distant sites rather than a real decrease in distant events. However, this substantial delay is worthwhile in young patients and determined the statistically difference between the untreated and treated groups. In Italy, the participating Institutions regularly offer adjuvant chemotherapy to patients presenting with the same high-risk characteristics. The role of Adjuvant Chemotherapy in the treatment of patients with soft-tissue sarcomas remains controversial despite a number of randomized trials and several meta-analyses. Of the several, mostly small, randomized trials of doxorubicin-based chemotherapy with varying eligibility criteria regarding size, grade, and primary tumor site, only one showed survival benefit. The NCI study was the first to indicate that extremity tumors might benefit to a greater extent than those of other primary sites. Only one study showed better disease-free survival in the observation group than in the chemotherapy group, whereas 8/9 studies showed better disease-free survival. Moreover, while none of the studies showed improved overall survival for the control group (one showed equal survival), 8/ 9 showed improved survival in the adjuvant chemotherapy group. Zalupsky and Baker were the first to perform such a meta-analysis using the published data on 926 patients with extremity sarcomas included in these studies. The meta-analysis demonstrated statistically significant improvement in both disease-free survival and overall survival. The absolute improvement in disease-free survival at 10 years was 15% (p<.0001), and absolute improvement in survival at 10 years was 10% (p=.0005). This study was criticized severely because it used published data rather than raw data. Formal results of a meta-analysis of individual patient data showed statistically significant improvement in local-relapse-free survival, distant-metastasis-free survival, and overall disease-free survival with a trend (p = 0.12) for improved survival. For the 886 patients with extremity soft-tissue sarcomas, there was statistically significant improvement in distant-metastasis-free survival, in overall disease-free survival, and overall survival. The risk of relapse (local and distant) decreased by 32% (absolute improvement at 10 years, 15%), the risk of distant metastasis decreased by 34% (absolute Trial #/arm Eligible patients Follow-up (median) 5 yr% 10 yr% LR  RFS  OS  LR  RFS  OS   62771 control  172  >120 mos  30  46  62  30  45  54  CT  145  16  60  64  19  57  54   62874 control  67  88 mos  12  52  64  CT  67  12  56  65 improvement at 10 years, 13%), and the risk of death decreased by 20% (absolute improvement at 10 years, 8%). 4 In the subset analysis of the same NCI study for retroperitoneal sarcomas, the survival of the control group is superior to the treatment group. Of the 12 randomized trials, the survival of the observation arm exceeds that of the chemotherapy arm in 3 studies (Mayo Clinic, Eastern Cooperative Oncology Group (ECOG), Scandinavian study). Doxorubicin-associated cardiotoxicity has occurred in about 10% of treated patients, occasionally contributing to treatment-related deaths. Based on these data, adjuvant chemotherapy should be considered investigational for adult soft tissue sarcomas of any primary site. A meta-analysis of individual patient data from all randomized adjuvant trials in sarcoma included data from 1568 patients. Adjuvant chemotherapy improved the time to local and distant recurrence-free survival (hazard ratios 0.73 and 0.70 with p-values of 0.016 and 0.0003, respectively). However, for overall survival, the absolute difference was a nonsignificant 4% advantage for chemotherapy and a hazard ratio of 0.89 (p = 0.12). 6 Randomized trials thus far of ifosfamide and doxorubicin based regimens are small with short follow-up, but will be of interest.
Is Doxorubicin really the standard treatment of advanced soft tissue sarcomas? T. ALVEGAARD (Southern Swedish Regional Tumour Registry, University Hospital, Lund, Sweden) Introduction: Adult soft tissue sarcoma (STS) is considered to be moderately sensitive to chemotherapy, with some reports suggesting that tumours of high-grade malignancy respond better than low-grade tumours. Doxorubicin and ifosfamide are generally considered to be the most active agents, and aggressive combination regimens have yielded response rates of around 45%. However, the role of chemotherapy in prolonging survival is still undefined in advanced disease and there is a need for the development of new chemotherapy approaches. Etoposide is considered to have low activity in adult STS. However, a recent study suggested that the activity of etoposide is considerably higher when administered as a prolonged infusion, taking advantage of the high cell cycle phase specificity of this agent. Combined with a moderate ifosfamide dose (4500 mg/m2), etoposide 600 mg/m2 given as a 72 h infusion yielded a 40% overall response rate in high-grade adult STS. This finding prompted the Scandinavian Sarcoma Group (SSG) to perform a prospective phase II trial to establish the level of activity for this regimen in adult STS. The study also addressed the possibility of dose escalation with the addition of granulocyte colony-stimulating factor (G-CSF) (VIG regimen), and analysed the impact of G-CSF on haematological toxicity. Finally, in selected patients, the study analysed disease-free and overall survival after chemotherapy and surgical removal of all identifiable disease.
Patients and methods:
The SSG 10/91 study was open to patients aged 15-70 years, with WHO performance status 0-2, histologically proven soft tissue sarcoma and measurable locally advanced or metastatic STS. Before chemotherapy, tumour measurements were taken by CT of MRI (magnetic resonance image) scans. Tumours of all malignancy grades were eligible, but small-cell STS (extraskeletal Ewing's sarcoma, primitive neuroectodermal tumours and undifferentiated variants) were ineligible, as were patients treated with radiotherapy to the indicator lesion(s) during the preceding 2 months. Other requirements were adequate renal function (creatinine clearance >70ml/min), WBC count >3.0 × 109/1 and platelet count >100 × 109/1. Of 92 eligible patients (median age 51 years), 85% had tumours of high-grade malignancy and 82% had metastatic disease. Chemotherapy, the baseline dose, consisted of etoposide 600 mg/m2 as a 72 h infusion and ifosfamide 1500 mg/m2/day for 3 days, followed by G-CSF support. Stepwise 10% dose escalations were performed depending on haematological toxicity. For patients considered operable after induction chemotherapy, surgical resection of all identifiable residual tumours was attempted.
Results: Complete and partial response rates were 11% and 31%, for an overall response rate of 42% (95% CI 31-52%). Forty-eight per cent of courses were dose escalated by a median of 20%. Complete responders had significantly higher, and patients with progressive disease had significantly lower, dose levels than other patients. None of the 20 patients with liver metastases responded despite high dose levels. The addition of G-CSF led to significantly higher dose levels, improved schedule adherence and less haematological toxicity, but no apparent increase in response rate.
Discussion: The present study demonstrated a high overall response rate (42%) for the present etoposide/ifosfamide combination. The present response rate is similar to that reported for the most potent ifosfamide/doxorubicin combinations. However, there is still controversy regarding whether combination chemotherapy is in fact superior to single-agent doxorubicin in adult STS. In randomised studies, response rates are commonly lower than in preceding phase II studies, as demonstrated in a recent randomised EORTC study where no difference could be found between doxorubicin alone, a doxorubicin/ifosfamide combination and CYVADIC. Considering the low level of non-haematological toxicity observed in this study, the VIG-regimen may be an attractive alternative to doxorubicin-containing chemotherapy. The study supports the concept that surgical removal of metastatic disease may prolong survival and that some patients may be cured by metastasectomy. An escalated dose of etoposide adm! inistered as a prolonged infusion may increase this agent's activity against STS, taking advantage of phase specificity. The VIG regimen is well tolerated, and the addition of G-CSF appears to reduce haematological toxicity and the incidence of neutropenic fever, to allow dose escalation and to improve schedule adherence. On the other hand, dose-intensified combinations, still as part of study protocols, had to be always proposed in highly selected patients with highly chemosensitive-advanced sarcomas.
In addition, the well-known discrepancy between clinical and histological response in locally advanced soft tissue sarcoma treated with preoperative chemotherapy can be easily applied to metastatic sarcomas. Histological responses could be a more accurate predictor of chemosensitivity than clinical responses, making difficult to evaluate the actual impact of these new drugs on disease free and overall survival of these patients.
The experience of SFOP in the treatment of Ewing/PNET family of tumours O. OBERLIN (Institut Gustave Roussy, Villejuif, France)
The purposes of the SFOP EW88 study were 1) to improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and performing resection of the primary, as often as possible, 2) To identify prognostic factors. 141 patients with localised tumour were entered onto the trial between January 1988 and December 1992. Induction therapy consisted of 5 courses of Cytoxan, 150 mg/m2 × 7 days, followed by Doxorubicin, 35 mg/ m2 IV on day 8. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. Results: After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (> 30% of cells), p < 0.0001. The tumour volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. As size of the primary and response to chemotherapy are independently correlated with outcome. We could identify 3 risk groups on the base of these factors:
-The standard risk group included the tumours with good response to chemotherapy (less than 5% viable cells) and the small unresected tumours but who had good clinical response. Its disease-free survival was 75%. -The high risk group included the tumours with clinically or histologically poor response to chemotherapy (with more than 30% viable cells). Its disease-free survival was only 13%. -The intermediate risk group included the tumours with intermediate response to chemotherapy (between 5 to 30% viable cells) and the large unresected tumours but which had a good clinical response. It's disease-free survival was 44%.
The subsequent SFOP EW93 study was based on this risk groups.
In the intermediate risk group, the role of the adjunction of VP16 + ifosfamide to the previous chemotherapy was evaluated. In the high risk group, the value of high dose chemotherapy with stem cell support was addressed. The preliminary results of this study will be presented. 
Lessons from the EICESS 92 study

Ewing's sarcoma: the Italian experience and strategy PIERO PICCI, GAETANO BACCI, STEFANO FERRARI & MARIO MERCURI (For the Italian Sarcoma Group)
From 1972 to 1997, 494 patients with non-metastatic Ewing's family tumors, comprising Ewing's sarcoma, Askin tumor and peripheral neuro-ectodermal tumor (PNET), were treated according to 5 protocols. The strategies of chemotherapy treatment changed over the years: from 1972 to 1988, a 3-drug regimen with vincristine (V), doxorubicin (A) and cyclophosphamide (C) gave significantly worse oncologic results (10-yr DFS 28%) than those obtained with a 4-drug regimen with V-A-C and actinomycin D (Act) used either as adjuvant (10-yr DFS 52%) or as neo-adjuvant chemotherapy (10-yr DFS 46%). From 1988 ifosfamide (I) and etoposide (E) were added to the V-A-C-Act regimen. In a study conducted between 1988 and 1991 Ifosfamide and Etoposide were used in the maintenance phase added to V-A-C-Act without improving oncologic results (5-yr DFS 54%). In the subsequent study Ifosfamide was used from the induction phase added to V-A-C-Act, and Etoposide was used in the maintenance phase. With this protocol, 3-yr DFS was 78%. Strategies for local control also changed: in the first two adjuvant protocols radiation therapy (RxT) alone was used in 67%, and 49% of patients respectively, whereas in the last neoadjuvant protocol 72% of patients underwent surgical treatment. From 1993, a separate protocol for high-risk tumors (pelvis, axial skeleton and all sites metastatic) was activated.
A retrospective analysis on all patients, showed the importance of surgical treatment in local control and the strong prognostic significance of tumor necrosis induced by primary chemotherapy in surgically treated patients. In the first protocols the axial location of the tumor was an adverse prognostic factor, but in the last protocol axial and extremity tumors did not show a significantly different oncologic outcome. These data, and, particularly, the grade of chemotherapy induced necrosis, were used to define the different risk groups and the ongoing protocols. Results and discussion: Three patients were excluded for having sarcomatoid carcinomas. Remaining were 20 men and 11 women, median age 56 years. The most common location was the nasal cavity and paranasal sinuses, followed by the maxilla and alveolar ridge. After review, which changed the diagnosis in 9 cases (26%), the most common histological diagnoses were leiomyosarcoma (6 cases), synovial sarcoma (4) and haemangiopericytoma (4). Like others, we saw no liposarcomas, but a relatively high proportion of borderline malignancies. 28 patients underwent primary surgery with curative intent, while 3 patients had a biopsy only. 8 received post-operative irradiation and 1 patient received irradiation as sole treatment. Only 4 patients received adjuvant chemotherapy. Mean follow up time was 28 months (range 1-127 months), with 19 patients (61%) recurrence free; 8 of these had borderline malignancies (4 haemangiopericytomas, 3 haemangioendotheliomas, 1 aggressive fibromatosis). 9 (29%) had died from their disease-5 of them with distant metastases and only 2 with lymph node metastases.
Abstracts-Posters
Conclusion:
Head and neck STT differ in their composition from those of other sites. Because of their rarity, they present a diagnostic as well as therapeutic challenge. Treatment should be centralized and clinical databases established in order to collect experience, preferably in intergroup trials. Purpose: At BCCA aggressive fibromatosis is treated using the same oncological principles as sarcomas. The following is an audit of this approach compared with patients treated elsewhere and seen later in the course of the disease. Patients over 16 years old seen at BCCA from 1980 to 1993 were reviewed. Method: All new patients had clinical examination and CT or MR scans prior to biopsy. Patients with a biopsy or excision performed elsewhere were also scanned. All pathology was reviewed at BCCA. Treatment was by wide excision with radiotherapy when either surgical margins were narrow or to enable limb sparing. For patients previously resected and found to have a marginal excision, a re-excision of the surgical bed was performed and treatment considered as of BCCA.
Results: A total of 48 patients were seen and the disease specific survival is 46/48 (92%). The disease-free survival is 48% at 5 years and 90% of relapses were within 2 years. Of patients treated at BCCA 3/13 relapsed against 26/35 treated elsewhere. Of patients treated with radiotherapy 2/12 relapsed against 27/36 without radiotherapy. Discussion: The indication is that a specialized centre may attain better local control and radiotherapy may have a central role. We have not assessed the toxicity and resultant function from this approach to a disease, which is rarely fatal.
Fibromatosis of the neck: a review of 18 cases C.K. HUANG, S.D. NELSON & T. CALCATERRA (University of California Los Angeles Medical Center)
Purpose: Fibromatosis is a histologically benign, clinically aggressive tumor with a tendency to invade adjacent structures and locally recur. Fibromatosis of the neck is challenging as nearby important structures increase morbidity and make surgical excision difficult. We report a series of fibromatosis of the neck and discuss the challenges in its treatment.
Patients: The study consisted of 18 patients with fibromatosis of the neck seen at our institution. The clinical data was collected retrospectively from patient charts and all slides were reviewed by one pathologist.
Results: Patient age ranged from 20-72 with a female to male ratio of 13 to 4. All patients presented with mass, about half (n = 9) had accompanying pain, and a few had decreased mobility or Horner's syndrome. All patients underwent an attempt at a wide surgical excision. Gross margins could not be obtained in 5 patients whose tumor invaded the spine or base of skull. Microscopically negative margins were obtained on only three patients. Three patients received adjuvant radiation therapy. There was an overall recurrence rate of 47% (n = 8) after an average disease free interval of 16 months. Recurrent disease was treated with re-excision, re-excision with radiation, or chemotherapy. Discussion: There is no consensus on the best treatment for fibromatosis of the neck. Though the current recommendation is a wide surgical excision, it cannot be shown to eliminate disease or prevent recurrence. A radical surgery is often limited by the anatomy of the neck. Therefore, other treatment methods should be considered for fibromatosis of the neck. Introduction: Most outcome studies to determine the effectiveness of soft tissue sarcoma (STS) therapy span a long period of time and involve several different therapeutic strategies. Methods: From March 1988 to March 1994, 101 patients underwent surgery for primary STS of the extremities or trunk. All patients were operated on by the same surgeon. Early re-excision was made after inadequate primary resection. Stepwise logistic regression was used to identify the important predictors of death. Cox regression models and Kaplan-Meier curves were used to assess time-related survival.
Results: Mean age of patients was 48 (range 15-84) years, 50% were female. The STS was located at the proximal extremity in 61% of all patients; 23% of the sarcomas were at the trunk, and 16% were distributed in the distal extremities. In 77% of patients, a resection with wide margins (R0) was achieved. In cases of R1 (n = 19) and R2 (n = 4) patients either denied reoperation or a palliative resection was performed. Postoperative radiation therapy and chemotherapy were administered in 44% and 17% of all patients, resp. The overall survivorship was 83.2% (mean follow-up 36 months). The survival rate was 90% at 1 year and 84% at 3 years. Multivariate risk factors influencing survival were tumor grade (p = .02), positive regional lymph nodes (p<.01), and location (p = .03). Local recurrence was not associated with increased mortality (p = .18). Patients with positive regional lymph nodes (p<.001), distant metastases (p<.001), and G3 tumors (p<.01) had shorter survival times.
Conclusions: Improvements in survival of patients with STS can be achieved with the use of complete excision within the anatomical compartment at initial surgery. Radiation therapy shall be performed in all cases of R1/R2 resections. High-risk patients without wide resection margins and G3 tumors may benefit most from this strategy.
Central nervous system metastasis from sarcomas: still an unresolved problem (Oncologia, Ospedale Gradenigo, Torino, Italy) Soft tissue and bone sarcomas rarely cause CNS metastasis (<1%). We reviewed 19 cases of brain and medullar metastasis between 1990 and 2000. There were 10 males and 9 females, median age 48 (17-66). PS 1-3 ECOG. Histological subtypes: 7 leiomyosarcomas, 3 MFH, 2 undifferentiated, 1 clear-cells, 1 pleomorfic liposarcoma, 1 schwannoma, 1 synovialsarcoma, 1 chondrosarcoma, 1 small-cell bone sarcoma, 1 extraosseous Ewing sarcoma. The two last determined medullar metastasis. Primary sites were: 7 visceral organs, 9 extremities, 2 trunk, 1 vertebral body. 15 pts had a high-grade sarcoma. 9 pts had multiple brain mets and 10 unique. All patients were heavily pre-treated: all received surgical treatment of primary tumour and 7 adjuvant chemotherapy (CT). All 19 patients were treated with CT when disease relapsed, 7 received a second-line therapy, 6 had a thirdline. Median time to relapse was 30 months (11-54). 16 patients received palliative CNS radiotherapy (RT) (15 Gy). Five patients had platinum-based CT. All patients had anti-oedema therapy. Median survival from diagnosis of CNS mets was 4. Purpose: To evaluate the occurrence of soft tissue sarcoma (sts) after radiation therapy and to investigate treatment strategy and prognosis.
Patients and methods:
In this Dutch multi-institutional study records of 101 (preliminary) patients were retrospectively reviewed. Patients were eligible if they had a diagnosis of STS that occurred after sufficient latency following radiation therapy for a histologically proven distinct primary tumour and originated in the vicinity of the irradiated area. The investigated parameters included age at diagnosis, type of irradiation, dose delivered, tumour histology, anatomic location and interval between these tumours, treatment of the sarcoma, histology and follow-up.
Results: Preliminary results showed that the median age at the time of diagnosis of the primary was 47.3 years (11-86) and the median interval between irradiation and diagnosis of the sarcoma was 11.2 years (2-38). The median dose delivered to the primary was 47.3 Gy (16-75). Seventeen patients had developed a STS on the edge of the radiation field. Nineteen patients were seen with an angiosarcoma of the breast after breast cancer. Survival after diagnosis of sarcoma was generally poor (median 29 months). Discussion: The induction of soft tissue sarcoma after radiation therapy is a rare but serious complication. Nowadays follow-up is sufficient to evaluate the different aspects of postradiation STS as will be presented in this study and side studies as case control-and dose deliverance studies are in progress. Purpose: The knowledge that gastrointestinal stromal tumors (GIST) usually express the c-kit proto-oncogene product, a transmembrane tyrosine-kinase receptor (CD117), has now established them as a distinct entity. Hence we found it of interest to review our cases. Methods: Pathological review of GISTs from the period 1990-2000 with supplementary immunohistochemistry. Results: 31 cases were found, of which the first was registered in 1994, the majority appearing after 1997. 15 were females, 16 males, aged 42-88 years with most patients older than 55 years. 13 cases were malignant, 5 of borderline malignancy and 13 benign. One was a GANT, one presented as liver metastasis only, and a patient with neurofibromatosis had multiple benign GISTs.14 tumors were located in the stomach, 9 in the small bowel, 1 in the rectum and 6 in the abdomen. All tumors except one expressed CD117 and 23 tumors CD34. 30 were vimentin, 5 actin, 2 desmin and 25 bcl-2 positive. HMB45, CK, S-100 and CD99 were negative, NSE often inconclusive. EM, performed in 5 cases, revealed no specialized cell type. Some 100 other mesenchymal gastrointestinal tumors were encountered, but not yet reviewed. Of these more than half were leiomyomatous, evenly distributed between benign and malignant, the remainder a smaller number of fibrous, neurogenic, histiocytic, vascular and un! classifiable benign/malignant tumors. Conclusion: Our material confirms the high frequency of CD117-positivity, justifying GIST to be diagnosed as a separate entity, thereby making possible a specific modality of postoperative treatment. We intend to complete the study by collecting clinical information, hoping to learn more about this tumor's biology.
Gastrointestinal stromal tumours
PET and MRI co-registration in pre-and post treatment evaluation of bone and soft tissue sarcoma. (Centre Léon Bérard, Hopital Edouard Herriot, Lyon, France) Open biopsy is considered as standard practice for the diagnosis of soft-tissue sarcoma (STS). Core needle biopsy (CNB) is an alternative, with minimal morbidity and cost, but with a possible risk of diagnostic inaccuracy. We conducted a retrospective study of the accuracy of CNB for the diagnosis of STM.
Method: All adult patients in whom a CNB was performed for the diagnosis of STM between 1994 and 2000 were selected. Sensibility (Se), specificity (Sp), positive (PPV) and negative (NPV) predictive value were determined for the diagnosis of malignancy (yes or no), connective tumor (i. Results: Overall, the review has so far led to a change in diagnosis in 131 out of 273 cases (48%). Previously, the most common subgroups were malignant fibrous histiocytoma (MFH): 27%, liposarcoma: 21%, fibrosarcoma: 11%, leiomyosarcoma: 11%, and synovial sarcoma: 8%. Most were distributed fairly evenly over time, but 65% of the MFHs were diagnosed in the 3rd quarter of the period . 84% of the fibrosarcomas and 73% of the malignant fibrous histiocytomas were reclassified, compared with only 19% of the synovial sarcomas, 18% of the liposarcomas, and 13% of the leiomyosarcomas. After review, the largest subgroup became the liposarcomas (22%), leiomyosarcomas (19%), synovial sarcomas (14%), MFHs incl. myxofibrosarcomas (10%), with 11% unclassified (NOS). Five benign lesions were identified: two cases of nodular fasciitis, two lipomas (with degenerative changes), and one aneurysmal fibrous histiocytoma. Among the fibrosarcomas were five fibromatoses (historically! considered 'fibrosarcomas grade_'). New entities were: two cases of sclerosing epithelioid fibrosarcoma and one low-grade fibromyxoid sarcoma. Discussion: When using historical material, e.g. for the purpose of evaluating possible prognostic factors or new molecular biological diagnostic markers, pathological review following current diagnostical criteria should be mandatory in order to avoid statistical contamination of the study population. Primary tumors were leiomyosarcomas (n = 13, 23%), MFH (n = 10, 19%), malignant peripheral nerve sheath tumour (n = 6, 13%) and 23 tumors of 11 other entities. 42% of patients were already treated with primary tumors in our institution. Primary tumors were located subcutaneously in 12 patients, subfascially in 25 patients and in 15 patients in parenchymatours organs. 50% of primary tumors were poorly differentiated, while 30% were moderate and 20% were well differentiated. 29% of primary tumors were resected achieving wide margins (R0), 81% R1. In 12.5% of patients distant metastases were present at initial diagnosis. In 40 patients, chemotherapy were administered (not in randomized trials), 26 of these after diagnosis of pulmonary metastases. In 28 patients local recurrence occurred, in 25 of these before or simultanously with pulmonary metastases. Patients were operated using thoracotomy or sternotomy, no patient was operated using thoracoscopy. Up to 4 operations and up to 38 pulmonary tumors were resected. At the end of follow-up, 14 patients are alive, while 38 died due to tumor disease. Mean survival time was 36.5 months and 19.5 months after metastasectomy. No significant statistical parameters were found associated with reduced survival.
Conclusion:
Though most patients will eventually die due to tumor disease, some curations are noted and overall survival is better than in most other malignant diseases. Even recurrent metastasectomy may be indicated in selected patients. 
months).
Results: Fourteen patients (56%) are currently alive and deseasefree, with the follow-up from 1 year 3 months to 19 years (median 7 years 6 months); 2 died of other deseases, 9 died of sarcoma (4 of metastases and 5 of metastases and simultaneous local recurrence) at a mean (SD) interval of 15 months after surgery (range, 6-25 months). One patient was lost from follow-up 6 months after surgery; he was not resident of Slovenia. Of 25 patients, 2 developed local recurrence without metastasis 6 months and 4 years 3 months after surgery (median 2 years 4 months). The bone was reconstructed in 6 patients (prosthesis in 3, vascularised fibular graft in 2, and intraoperative extracorporeal autogenous sterilised bone graft in one). In 14 alive patients, hand-elbow function is excellent in 7, good in 6, and fair in 1 patient. Objective: Curative resection of extended sarcomas of the proximal extremities can often only be achieved by major amputations due to infiltration of vital structures. Material and Methods: 15 patients (10m:5f) with a mean age of 55 (25-81) years were treated by either exarticulation of the shoulder (n = 3) or hip (n = 5), hemipelvectomy (n = 2) or interscapulothoracic amputation (n = 5). 2 patients had a primary manifestation of their tumour, all others had recurrences. The primary manifestation was 25 (0-212) months before and the patients had 3 (0-5) prior operations for the same disease. Curative resection (R0) was achieved in all cases. The majority of the tumours were poorly differentiated (GII: n = 6, GIII: n = 9). The hospital mortality was 6%, no major complications occurred. Results: After a median follow-up (after the amputation) of 30 (2-108) months 53% of the patients were still alive. 3 Patients (20%) had died tumour related, 3 due to unrelated diseases and one of unknown cause. The median survival time was 53 (2-321) months after primary manifestation of the disease and 21 (2-108) months after amputation. One patient developed pulmonary metastases 5 months after hemipelvectomy, one patient, now disease free, developed local recurrence after exarticulation of the shoulder and received R0 resection of the shoulder girdle stump. All other patients were also free of recurrence or metastases. Conclusion: Major amputation can be successful even in extended, recurrent and poorly differentiated sarcomas. Background: En bloc resection of the sciatic nerve with a malignant tumour of the pelvis or thigh was long considered an indication for an amputation because of the anticipated poor function. The authors describe the functional outcome of a group of patients who underwent a limb-sparing surgery in spite of the need to sacrifice the sciatic nerve. Materials and Methods: Between 1991 and 1999, the authors treated 12 patients who underwent limb-sparing resections of a malignant tumour of the thigh, buttock, or pelvis, all of which necessitated en bloc resection of a segment of the sciatic nerve with the tumour mass. There were eight females and four males, ranging in age from 2 to 73 (mean, 54 years). Diagnoses: soft-tissue sarcomas-8, metastatic bone disease-3, primary bone sarcomas-1. Anatomic locations: thigh-7, pelvis-4, buttock-1. Follow-up ranged from 10 to 102 months (mean, 30 months).
Results: At the most recent follow-up evaluation, eleven patients were ambulatory and only one patient was wheel chair bound. Of the ambulatory patients, only five patients required a walking aid (crutches or a cane); a long-leg brace was not required by any of these patients. Although all patients had an anesthetic ipsilateral foot, none had a pressure sore or required a secondary amputation. All ambulatory patients were satisfied with the functional outcome. Conclusion: Provided the femoral nerve is intact, the mere necessity to resect the sciatic nerve with a given tumor of the pelvis or thigh is not an indication for an amputation. Surgery B. Sourasky Medical Center, Tel Aviv Israel) Background: Beromun(B) (-rTNFa) is a highly potential antineoplastic agent. However, since its systemic administration in humans resulted in a life-threatening septic shock-like syndrome, its use was abandoned These systemic side effects were eliminated when TNF was administered via isolated limb perfusion (ILP). This method is now being used in order to prevent amputation ormutilating surgery in patients suffering from irresectable limb soft tissue sarcomas. Methods: During a 7-year period, 70 pts with high grade STS underwent 81 ILPs with high dose Berornun® (3-4mg) and Melphalan (1-1.5mg/kg). There were 37 males and 33 females. The mean age was 56 years (range 14-80 years). . 31 pts presented with recurrent and 40 with very extensive primary tumors. The tumors were located in the upper extremity in 13 pts and in the lower extremity in 57 pts. All pts were candidates for either amputation or extensive mutilating surgery. ILP was performed via the corresponding vessels proximal to the tumor. Resection of the residual tumor or tumor bed or limb was performed 6-8 weeks after ILP, and all reported responses were pathologically confirmed. Results: Marked tumor softening occurred within 48 hours, and in tumors protruding through the skin, hemorrhagic necrosis was evident within 24 hours. The overall response rate was 80%. 21 pts (30%) had a complete response and 40 (57%) had a PR. in 3 pts (11%), only minimal regression was observed (stabilization of disease). Operative mortality was 3% (2 pts). Limb sparing was achieved in 82% (62/70 pts). Amputation was performed in 8 pts. Within a follow-up period of 2-76 months )median 24 m), 30 pts (43%) are dead, 31 (44%) are alive with no evidence of disease (median 49 m), and 9 (13%) are alive with disease. Local recurrence occurred in 16/60 evaluable pts (26%). Limb salvage and survival rates were not significantly different for gender, age, primary vs recurrent tumor, or tumor location. Mortality was significantly higher for multifocal disease (73% vs 29%)(p<0.05). Limb salvage rates were also not different for the various histological subtypes. There was trend towards higher response rates in synovial and clear cell sarcomas. Conclusions: The combination of Berornun® and Melphalan given via ILP appears to be effective in pts with advanced STS confined to the limb, achieving a high response rate and limb preservation. Purpose: After inadequate margins in Soft Tissue Sarcoma (STS), there is no general agreement about further treatment (surgery and or radiotherapy). This is particularly evident with no evidence of clinical or radiological disease. We report our experience, comparing two groups of patients: one, primarily observed in our Center (group A), and one inadequately operated elsewhere (group B). Both groups underwent surgery, and, when feasible, brachytherapy and external radiation therapy. Subjects: From 1987 to 1999, 241 patients affected by STS of limbs have been treated in our Center: 68 where first observations (group A), 75 where primary radicalizations (group B). Ninetyeight have been excluded since affected by local recurrence (operated elsewhere) or amputated. High grade STS were represented in 68% of group A and 80% of group B while a location distal to knee or elbow was in 35% of group A and 63% of group B.
Primary radicalization plus radiotherapy after inadequate
The average time of radicalization after the previous surgery was three months and viable tumoural cells were found in 45% of specimens of group B. Free or rotational flaps, for covering the loss of substance, were performed in 20% of group A and in 44% of group B. Brachytherapy was applied in 63% of group A and in 57% of group B, while conventional radiation therapy was performed in 79% of group A and 67% of group B. Results: At an average F.U. of 54 months (5-150), 76% of patients were continuous disease free in both groups. Local recurrence occurred in 3% of group A and in 5% of group B. In group B, as far as the local recurrence rate is concerned, 6% appeared in positive specimens and 5% in negative specimens. Functional results (MSTS) were rated as satisfactory in 80% of group A and 88% of group B. Discussion: After inadequate surgery of STS, surgical reprises associated to adjuvant radiation therapy showed to be efficacy in local control, even in distal location, although with high percentage of free flaps, not impairing the functional results. The impact of adjuvant RT on both local control and distant relapse is not clearly established after wide excision of extremity STS. Purpose: We performed a retrospective analysis on behavior of patients (pts) who underwent a large resection (first or second resection) in our institution and received or not adjuvant RT: All histological specimens were carefully analyzed and only pts with free tumoral margins (ftm) were retained for analysis. Histopathological classification was as following: minimal R0 (mR0) resection (ftm<10mm) and optimal R0 (oR0) resection (ftm >10 mm). Patients: from 1975 to 1996, 133 pts with a median age of 44 yrs were operated at IGR. The median tumor size was 6cm. Ninetythree pts (70%) primary resected in other centers, were reoperated and residual tumor cells (RTC) were found in 54% of pts. Sixtynine pts (17 oR0 and 52 mR0) received adjuvant RT and 64 pts did not (54 oR0 and 10 mR0). Characteristics of pts were similar in both groups. Results: Median follow-up time was 1o yrs (3 or 25). Thirty-three pts had a local relapse: 11 in the RT group and 22 pts in the control group (p 0.01). Grade and ftm are correlated to OS and adjuvant RT to RFS. A positive impact of RT on local control was only seen in pts with a mR0 resection (p = 0.005) and in pts with RTC after reexcision (p = 0.001). RT has no influence on 5 and 10 yr-OS. Conclusion: optimal resection seems to be the best predictive parameter for a favorable outcome in term of local control in localized STS. Adjuvant RT is indicated in mR0 resections and in case of RTC after definitive surgery, but its role after oR0 resection has to be validated by a prospective randomized trial. Since 1988 we have been collecting data regarding pts. with histologically proven diagnosis of STS, treated with conservative surgery and EBRT plus intraoperative BT, in order to assess local control and late effects. In our files were registered 64 pts. with primary localization as follows: 54 extremities, 3 head-neck, 3 trunck-abdomen, 4 genito-urinary system. All pts. underwent BT with intraoperative implant up to a total dose of 15-25 Gy. 7 of them previously received 40-50 Gy of preoperative EBRT, 57 received EBRT roughly a week after BT. 4 had hyperthermic antiblastic intraartherial perfusion before operation. 5 paediatric pts. were treated only with BT. No one had considerable radiotherapy related acute toxicity. At a median follow-up of 4 years, we registered a local relapse free survival of 95.3%. No severe late effects are observed at this dose of BT. BT allows to give RT avoiding side effects related to external beams, moreover it reduces the time for the local treatment, anticipating chemotherapy if required. Purpose: This phase-II study was designed to assess the role of neoadjuvant chemoradiotherapy and extremity preserving surgery on the local control and survival of the patients having extremity soft tissue sarcomas. The histological response of the tumors to the neoadjuvant therapy was also assessed.
Local control after external beam radiation therapy (EBRT
Neoadjuvant
Patients: Between 1994 September-2000 May 68 cases were included to the study having the median age 44 (17-77). M/F ratio was 1.7. The diagnosis was done with tru-cut biopsy; the most common subtype was liposarcoma.
Methods: All cases were treated with 50.4 Gy (2Gy/day, 5 fractions/week) and 3 cycles of concurrent chemotherapy (mitomycin 8mg/m2, doxorubicin 40mg/m2, cisplatinum 60 mg/m2). One month after the end of neoadjuvant therapy wide excision was performed in 52 cases and amputation in 2 cases. 14 patients were not operated due to refusal of operation or metastatic outcome. 2-3 cycles of additional chemotherapy was given in 11 cases. Results: After a median follow-up of 27 months (3-74), local recurrence was developed in 4, lymph node metastasis in one and distant metastasis in 21. Local recurrence free survival was 88.8% and distant metastasis free survival was 49.1% at 3 years. 17 cases were lost due to tumor progression; cause specific survival was 51.9% at 3 years. Discussion: Concurrent neoadjuvant chemoradiotherapy in soft tissue sarcomas is feasible. Further randomized studies are needed to clarify the role of neoadjuvant radiochemotherapy on the local control and survival of soft tissue sarcomas. Re excision of limb's sarcoma after inadequate surgery finds 45 to 50% residual tumour cells.
The objective of this study is to determine the prevalence of residual tumour after marginal excision of retroperitoneal sarcoma (RPS).
Patients with residual mass on imaging or described by the medical report were excluded.
Among the 94 retroperitoneal sarcoma operated at Institut Gustave-Roussy between November 1997 and November 2000, ten underwent systematic re-excision. Initial surgery was in these cases marginal excision of the RPS with 4 effractions of the tumour. Median age of the patients was 41 years. FNLCC grade were grade 1 n = 4, grade 2 n = 3, grade 3 n = 3. 'En bloc' resection of the initial surgical area was performed with 5 colectomy, 6 muscle's resections, 1 posterior pelvectomy, 1 omentectomy, 1 duodeno-pancreatectomy, 1 nerve's excision. Results: Residual tumour was found in 7 patients (70%). Macroscopically obvious n = 3 (with 2 sarcomatosis) and microscopically n = 4. Surgical margins when residual tumour was found were R0 n = 4, R1 n = 3 (2 sarcomatosis) (UICC R classification). Postoperative treatments were: intra peritoneal chemotherapy n = 2, radiotherapy n = 3, chemotherapy n = 1. With a median follow up of 20 months, 4 recurrences occurred; the two patients with sarcomatosis and 2 patients with initial tumour's effraction but with no residual tumour found at re-excision. One recurrence was both local and metastatic. Purpose: Retroperitoneal sarcomas and GISTS are usually a challenging therapeutical issue, with high recurrence rates. The purpose of this work was to evaluate, within a phase 1 study, the feasibility of cytoreductive surgery (CS) in combination with hyperthermic intraperitoneal intraoperative chemotherapy (HIIC) with doxorubicin and cisplatin. Patients and methods: 18 out of 32 enrolled patients had recurrent or multiple retroperitoneal sarcomas/GISTS underwent HIIC with doxorubicin and cisplatin at escalating dose (5-19 mg/l and 20-43 mg/l, respectively), after CS (tumor residues < 3 mm). Loco-regional toxicity was evaluated according to modified Ozols' criteria while systemic according to WHO criteria. Follow-up controls were scheduled monthly for the first 3 months, then every three months until 18th month and then every six months.
Results: Post-operative complications occurred in 4 patients (2 septic shock, 1 fistula and 1 pneumothorax). Loco-regional toxicity was grade 1 in 5 patients, grade 2 in 3 and grade 4 in one that required re-operation for adhesiolysis after 20 days. Grade 1 hematological toxicity was reported in 3 patients, while persistent fever in another 3. After a median follow up of 24 months (range 12-36), 9 patients are NED (50%), 6 (33%) are AWD, 2 (11%) DOC and 1(5%) die of tumor progression. 7(39%) patients developed local recurrence and 3 of them had re-do HIIC.
Conclusions: HIIC in combination with CS is feasible and seems to improve local disease control in this subset of patients, with acceptable toxicity and morbidity. Large series is needed to confirm these results.
respiratory failure after a complicated post operative course but had DP. Two pts remain alive: 1 HLT pt 47 m post POD with cerebral metastases as the only site of recurrence!, and 1 HT pt free of disease 67 m post transplant. Discussion: Orthoptic HT or HLT is a technically feasible treatment for highly selected pts with localized advanced PCS. The high incidence of metastatic disease may limit the usefulness of HT or HLT. Chemotherapy resistance of cancer cells is the major limitation to this treatment approach. Multidrug resistance (MDR) in many human cancers may be due to the expression of the multidrug transport P-glycoprotein (Pgp). New drugs developed specifically to inhibit Pgp, such as Valspodar (PSC 833-Novartis), may provide clinicians with more potent and specific inhibitors for MDR modulation trials. We have investigated the cytotoxic effect of doxorubicin (DXR) combined with PSC 833 on cultured human sarcoma cell lines (U-2 OS, U-2/neo8, U-2 OS/DX580, OS/DX35, OS/DX117.1, OS/ DX117.2), expressing various levels of Pgp. The major cytotoxic effects were achieved through the continuous presence of PSC 833 in the medium, therefore showing that sustained effective concentration of PSC 833 during DXR administration is needed in order to obtain maximal effect. We have furthermore evaluated Pgp expression in sporadic canine osteosarcoma, confirming its high incidence. These data let us develop a novel protocol for the treatment of canine osteosarcoma using PSC 833 and DXR. We have evaluated the pharmacokinetic, toxicity and side effects of this combined treatment that resulted active and well tolerated. Our studies, considered with the previous literature, support a rational to develop a risk-adapted strategy in human patients with Pgp positive cancer at clinical onset that could be treated with combined regimes including DXR and PSC 833, in order to revert multidrug resistance. Since soft tissue sarcomas are shown to express MDR phenotype in a high percentage of cases, while present chemotherapeutic treatments of these tumours need major improvements, we therefore propose to develop a clinical trial using DXR in association with PSC 833 in sarcoma patients whose primary tumours were shown to express detectable levels of Pgp. naturally occurred in the culture and was not due to an increased cell proliferation rate. TZD prevented apoptosis also when induced by staurosporin. The TZD-mediated survival effect correlated with the activation of Akt, a well known mediator of survival stimuli.
Use of valspodar and
Discussion: Our results suggest that PPAR activation may be a key element that inhibits cell death and promotes tumor growth.
Results from this study caution against the use of PPAR_chemical agonist on patients with OS and suggest that PPAR activation by natural ligands may be a key step in OS development.
